Last reviewed · How we verify
NCT05234060
Study of People's Profile Living in France Who Could be Interested in the Use of a Nanohydroxyapatite Toothpaste
trial in Dental Caries in 200 participants. Completed in 1 February 2021.
30 January 2021
Quick facts
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 May 2020 |
| Primary completion | 30 January 2021 |
| Estimated completion | 1 February 2021 |
| Sites | 1 location across France |
Conditions studied
- Dental Caries — all drugs for Dental Caries →
- Hydroxyapatite — all drugs for Hydroxyapatite →
Sponsor
University Hospital, Montpellier
Who can join
18 and older, any sex, with Dental Caries or Hydroxyapatite. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nano-hydroxyapatite is an interesting candidate to be a substitute for fluor in toothpastes or a complement to fluorides in order to prevent caries. The objective of this transversal descriptive study is to evaluate the profiles of people living in France who could be interested in using a nano-hydroxyapatite based toothpaste. Participants in this transversal descriptive study have been chosen by a self-administered method. Before answering 16 questions, the participants were asked to watch a short video describing the main concepts to know about fluoridated toothpastes and nano-hydoxyapatite toothpastes. Pros and cons of each one them were mentioned. In order to compare the answers, pivot tables have been produced.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05234060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dental Caries
Currently open trials in the same condition.
- NCT06787261 — Involvement of Archaea in Carious Disease · NA · recruiting
- NCT06753669 — Mothers' Action Project for Child Health · NA · recruiting
- NCT07431463 — Effects of Different Remineralization Agents on the Progression of Non-Cavitated Approximal Carious Lesions in Primary T · NA · active not recruiting
- NCT07134114 — Occlusal Impact of Hall Crowns in Primary Molars · NA · recruiting
- NCT07181967 — SDF vs Fluoride Varnish for Streptococcus Mutans Reduction in Children · NA · recruiting
Other University Hospital, Montpellier trials
Trials by the same sponsor.
- NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
- NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
- NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05234060 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
- Last refreshed: 11 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05234060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing